Sign up to save your podcasts
Or
Share Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
View all episodes
By Bernard Marini, Anthony Perissinotti, et al.
4.5
2828 ratings
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
More shows like WolverHeme Happy Hour
View all
The Hematologist
26 Listeners
JAMA Clinical Reviews
496 Listeners
OncoPharm
185 Listeners
VJHemOnc Podcast
3 Listeners
The Peter Attia Drive
7,953 Listeners
Plenary Session - inactive due to federal service
755 Listeners
Treating Blood Cancers
12 Listeners
Blood Podcast
51 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Healthcare Unfiltered
134 Listeners
EHA Unplugged
1 Listeners
Two Onc Docs
169 Listeners
Blood Cancer Talks
48 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners
HemeTalks: Conversations in Hematology Education
3 Listeners